EBV primarily targets B lymphocytes by binding to the CD21 receptor on the cell surface. This interaction facilitates the entry of the virus into the host cell, where it can establish both lytic and latent infections. During latency, EBV persists in the B cells as an episome, allowing the virus to evade the host's immune system.
